Metabolic Reprogramming of Monocytes in Inflammatory Flares of Inflammatory Bowel Diseases

NCT06944873 | Not Yet Recruiting

• 1 other identifier: 38RC24.0363
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

Inflammatory bowel diseases, Crohn's disease and haemorrhagic rectocolitis, are pathologies that progress in flare-ups, impacting on patients' quality of life and functional or even vital prognosis. These inflammatory diseases require the use of immunosuppressive and immunomodulatory treatments, the side-effects of which can be significant, and the limited number of which sometimes puts patients and practitioners in a therapeutic impasse from which surgery is the only way out. It is therefore important to be able to develop new therapeutic approaches, ideally better tolerated, that can control inflammation during relapses. Monocytes are one of the main players in the inflammatory reaction. In the laboratory, we have developed a strategy for the metabolic reprogramming of these cells based on the use of oxygen microbubbles to modulate the inflammatory response of monocytes.

Conditions

Inflammatory Bowel Disease (IBD)

Keywords

Monocytes; Metabolic reprogramming

Outcome Measures

Primary Outcomes (1)

• Comparaison of reduction of concentration of inflammatory cytokines and chemokines in cells treated by oxygen microbubbles vs cells not treated

  Validation of inhibition of the production of inflammatory cytokines and chemokines by the monocytes treated by oxygen microbubbles

  up to 2 years

Secondary Outcomes (2)

• Comparaison of tissue factor expression at the membrane of monocytes treated by microbubbles vs monocytes not treated

  up to 2 years

• Comparaison of glucose metabolism rate in monocytes treated bu microbubbles vs not treated cells

  up to 2 years

Interventions

Blood test 4 EDTA tubes BIOLOGICAL

Blood test 4 EDTA tubes for biological check-up

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with IBD in severe relapse requiring hospitalisation for immunosuppressive therapy or endoscopy for relapse.

You may qualify if:

• Men and women over 18
• Managed at the CHUGA for a severe IBD flare-up requiring hospitalisation or endoscopy for flare-up
• Patient not objecting to the REPRO-MICI study

You may not qualify if:

• Patients protected by law (pregnant or breast-feeding women, minors, patients under guardianship or trusteeship, persons deprived of their liberty or hospitalised under duress).
• Patients with positive HIV, HBV or HCV serology.
• Patients with a positive ELISPOT with no history of treatment for latent tuberculosis.

Sponsors & Collaborators

• University Hospital, Grenoble: lead
• Institute for Advanced Biosciences (IAB), Grenoble: collaborator

Study Sites (1)

Grenoble Alpes University Hospital

La Tronche, 38700, France

Location

MeSH Terms

Conditions

Inflammatory Bowel Diseases

Condition Hierarchy (Ancestors)

Gastroenteritis; Gastrointestinal Diseases; Digestive System Diseases; Intestinal Diseases

Study Officials

• Marianne HUPE, MD PhD

  Grenoble Alpes University Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Marianne HUPE, MD PhD

CONTACT

+33446466912; mhupe@chu-grenoble.fr

Anna Borowik, PhD

CONTACT

+33476769314; aborowik@chu-grenoble.fr

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 13, 2025
• First Posted: April 25, 2025
• Study Start: July 1, 2026
• Primary Completion (Estimated): April 30, 2028
• Study Completion (Estimated): July 31, 2028
• Last Updated: May 19, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)